There are multiple chapters near you. Select your preferred chapter.

Aurinia Pharmaceuticals (AUPH) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall ...

Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...

WASHINGTON -- Lupus nephritis (LN) diagnosis could improve greatly if early results with a multimarker urine test are ...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) commends the American College of Rheumatology (ACR) for their 2024 evidence-based guidelines for the screening, treatment, and ...

The Lupus Foundation of America (LFA) is proud to honor two exceptional lupus researchers at the 2024 Evelyn V. Hess ...

Aurinia Pharmaceuticals (AUPH) has released an update. Aurinia Pharmaceuticals has unveiled new data underscoring the importance of early ...

Fate Therapeutics (NASDAQ:FATE) stock closed 12% higher Monday after soaring as much as 73% on news that the first patient in ...

Fate Therapeutics driven by positive Phase 1 Autoimmunity study results for its CAR T-cell therapy candidate FT819 in lupus ...

The American College of Rheumatology (ACR ... treatment, and management of lupus nephritis; advances in screening and diagnosis of RA-ILD; and controversies in the treatment of anticitrullinated ...

The sFlt-1/PlGF ratio did not effectively gauge future preeclampsia risk in pregnant patients with SLE and proteinuria.